Severe Acute Respiratory News and Research

RSS

Statins improve 28-day mortality in hospitalized COVID-19 patients

Now, researchers at Harvard Medical School showed that statin use reduced 28-day mortality in patients hospitalized with COVID-19. Both the new initiation of statins and continuing statin therapy reduced the risk of mortality.

8 Apr 2021

High SARS-CoV-2 attack rates linked to singing events

Now, a team of researchers from the Netherlands and Sweden demonstrates that airborne spread via infectious droplets or aerosols over longer distances of more than 1.5 meters due to singing is possible during singing events.

8 Apr 2021

More new SARS-CoV-2 variants are highly likely

In a recent report posted to the bioRxiv preprint server, researchers from the United Kingdom and Uganda reveal unique protein features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) relative to other representatives of Sarbecoviruses.

8 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

A new preprint research paper posted to the bioRxiv server reports on the ability of a set of neutralizing mouse antibodies to protect mice against multiple lineages of SARS-CoV-2.

8 Apr 2021

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.

8 Apr 2021

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Mobility tracking using cell phone data showing greater movement of people is a strong predictor of increased rates of COVID-19, according to new data in CMAJ (Canadian Medical Association Journal)

8 Apr 2021

The interaction between blood clotting and SARS-CoV-2 infection

Coagulopathy - a condition in which the blood's ability to clot is impaired, is recognized as a significant aspect of morbidity in COVID-19 patients. In a recent study, Prof Lewis Cantley and a team of researchers explored the role of coagulation factors in the SARS-CoV-2 infection. Their recent study is posted on the bioRxiv server.

7 Apr 2021

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

A new Morbidity and Mortality Weekly Report published by the U.S. Centers for Disease Control and Prevention (CDC) states that mRNA COVID-19 vaccines are highly effective in preventing SARS-CoV-2 infection in the real world. The report is based on a CDC study where it routinely tested prospective cohorts of health care professionals, first responders, and essential and frontline workers for SARS-CoV-2 infections.

7 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Makdasi et al. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.04.01.438035, https://www.biorxiv.org/content/10.1101/2021.04.01.438035v2

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.

7 Apr 2021

Researchers use South Korea Data to create new framework for COVID-19-vulnerable locales

Though the U.S. and South Korea recorded their first official COVID-19 case on the same day, January 20, 2020, there were notable differences in how each country would ultimately address what has become the world's most severe pandemic since 1918.

7 Apr 2021

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

The coronavirus disease (COVID-19) first emerged in late December 2019 in Wuhan, China. Though it has been more than one year since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported, it is still unclear how long the antibodies persist in those who have recovered.

7 Apr 2021

Natural selection and adaptation of SARS-CoV-2 in mammals

Researchers of the Hubei University of Medicine, China, have analyzed several mutations in different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from mammal species that suggest natural selection and host adaptation are occurring in the virus.

6 Apr 2021

Severe Acute Respiratory News and Research

Statins improve 28-day mortality in hospitalized COVID-19 patients

High SARS-CoV-2 attack rates linked to singing events

More new SARS-CoV-2 variants are highly likely

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

The interaction between blood clotting and SARS-CoV-2 infection

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers use South Korea Data to create new framework for COVID-19-vulnerable locales

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

Natural selection and adaptation of SARS-CoV-2 in mammals

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News